Comparative Pharmacology
Head-to-head clinical analysis: ACULAR versus ACUVAIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACULAR versus ACUVAIL.
ACULAR vs ACUVAIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
1 drop in the affected eye 4 times daily.
None Documented
None Documented
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Category C
Category C
NSAID Ophthalmic
NSAID Ophthalmic